OPGN OpGen Inc

OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its second quarter 2019 financial results after the close of the U.S. financial markets on Wednesday, August 7, 2019. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and business progress.

Dial-in Information U.S. Dial-In Number: (844) 420-8185             International Dial-In Number: (216) 562-0481           Conference ID: 7288909

Replay Dial-in Information U.S. Dial-In Number: (855) 859-2056    International Dial-In Number: (404) 537-3406 Conference ID: 7288909

Following the conclusion of the conference call, a replay will be available through August 13, 2019. The live, listen-only webcast of the conference call may also be accessed by visiting the investors section of the Company’s website at www.ir.opgen.com. A replay of the webcast will be available after the conclusion of the call and will be archived on the Company’s website for 90 days.

About OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. We are developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.

Our molecular diagnostics and informatics products, product candidates and services combine our Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with our proprietary, curated MDRO knowledgebase. We are working to deliver our products and services, some in development, to a global network of customers and partners. The Acuitas AMR Gene Panel (RUO) is intended for Research Use Only and is not for use in diagnostic procedures. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures. For more information, please visit www.opgen.com.

OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks of OpGen, Inc.

OpGen Contact: Michael Farmer Vice President, Marketing (240) 813-1284 mfarmer@opgen.com InvestorRelations@opgen.com

Press Contact: Matthew Bretzius FischTank Marketing and PR matt@fischtankpr.com

Investor Contacts: Joe Green Edison Group jgreen@edisongroup.com